All‐cause mortality · patients with acute peptic ulcer bleeding
High showed no clear difference in mortality compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Rebleeding · patients with acute peptic ulcer bleeding
High showed no clear difference in rebleeding compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Surgery · patients with acute peptic ulcer bleeding
High showed no clear difference in surgery compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Further EHT · patients with acute peptic ulcer bleeding
High showed no clear difference in further EHT compared with non‐high (medium or low) dose regimen (low certainty).
1 finding from 1 review
Length of hospital stay · patients with acute peptic ulcer bleeding
1 finding from 1 review
Blood transfusion · patients with acute peptic ulcer bleeding
1 finding from 1 review
Frequency of defecation (mean number of bowel movements per week) · patients aged 0 to 18 years with a diagnosis of functional constipation
1 finding from 1 review
Need for extra treatment · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes need for additional therapy compared with low dose PEG (very low certainty).
1 finding from 1 review
Faecal incontinence · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes faecal incontinence compared with low dose PEG (very low certainty).
1 finding from 1 review
Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation
It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).
1 finding from 1 review
Clinical relapse · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in clinical relapse compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Radiologic relapse · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).
1 finding from 1 review
Health related quality of life · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in symptoms · GORD in children over 1 year of age
1 finding from 1 review
Adverse events · GORD in children over 1 year of age
1 finding from 1 review
Endoscopic improvement (dichotomous) · GORD in children over 1 year of age
1 finding from 1 review